NCT02389621View on ClinicalTrials.gov

Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures

PHASE3CompletedINTERVENTIONAL
Enrollment

215

Participants

Timeline

Start Date

June 15, 2015

Primary Completion Date

April 5, 2017

Study Completion Date

April 19, 2017

Conditions
Chronic Liver DiseaseThrombocytopenia
Interventions
DRUG

Lusutrombopag

Tablets for oral administration

DRUG

Placebo

Tablets for oral administration

Sponsors

Lead Sponsor

Shionogi
All Listed Sponsors
lead

Shionogi

INDUSTRY

NCT02389621 - Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures | Biotech Hunter | Biotech Hunter